News
ORLANDO — In patients with active or chronic thyroid eye disease, veligrotug improved symptoms of proptosis and diplopia and clinical activity score, according to 15-week results of the THRIVE ...
Veligrotug demonstrated significant improvements in proptosis, diplopia, and clinical activity score among patients with active thyroid eye disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback